They've been selling your health data for decades.
We're going to send you the check.

On March 23, 2025, a genetic testing company called 23andMe filed for bankruptcy.

Fifteen million people had spit into a tube and trusted them with the most personal data they would ever generate — the genetic code that defined them, their families, and their predispositions to every disease known to medicine.

The bankruptcy court appointed a consumer privacy ombudsman. Twenty-seven state attorneys general filed a coalition lawsuit to block the sale. The Federal Trade Commission weighed in.

The court approved the sale anyway.

The data of fifteen million people sold for $305 million — about twenty dollars per person.

Of that $305 million, the fifteen million people whose DNA was sold received exactly zero dollars.

Not a penny. Not a participation right. Not even a phone call to ask permission.

This is not a tragedy. This is the business model.

Every prescription you fill, every lab test you take, every visit you make to your doctor — that data is being sold right now, behind your back, to companies whose names you will never see and whose checks you will never receive.

Major pharmaceutical companies collectively spend hundreds of millions of dollars each year licensing patient health data through commercial data brokers.

IQVIA, the largest healthcare data company in the world, holds five hundred million individual patient dossiers.

Epic, the dominant electronic health records system in American hospitals, has built a research network of two hundred million patient records.

The Palantir Federated Data Platform contract with the UK's National Health Service was signed for three hundred and thirty million pounds — to analyze data the patients themselves never consented to monetize.

The healthcare data economy is a multi-billion-dollar industry built entirely on information you generated, paid for, and own.

You have never been paid a dime.

We think that should change.

MyRxWallet is being built as the first healthcare platform designed from the ground up to put the economics of health data back where they belong: with the people who generated it.

When the platform launches, every member who enrolls will receive a sovereign digital identity called an NFT — a unique, non-transferable token that establishes their ownership of their health data on a federally-graded blockchain settlement rail.

When pharmaceutical companies, research institutions, or healthcare organizations want to license patient data — anonymized, de-identified, and consent-controlled — they will pay through the platform. Patients will receive eighty-five percent of every licensing royalty paid for their data. The platform retains fifteen percent to operate the infrastructure, the security layer, the legal compliance, and the federal-grade audit framework that makes the whole system work.

That royalty arrives in MRT — MyRxWallet's compensation token, designed as a closed-loop loyalty mechanism designed to be backed by MyRxWallet's one-point-one-five-billion-dollar Founder-committed treasury reserve, designated at the company level for that exact purpose.

Members will be able to redeem MRT for the things that actually matter to their health and their lives — their prescription costs through the platform's pharmacy network, their insurance copays through the platform's health plan products, their doctor visits through the platform's provider network, their wellness programs and preventive care, and through structured partnerships designed for launch, the lifestyle categories that turn earned MRT into earned life.

This is not a cryptocurrency speculation play. This is a closed-loop loyalty economy designed to be backed by real treasury assets and real licensing revenue, designed to comply with the Securities and Exchange Commission's framework for compensation tokens, the Anti-Kickback Statute's safe harbors for healthcare programs, and HIPAA's requirements for protected health information.

The blockchain is not the point. The blockchain is the trust layer that makes the whole system auditable end-to-end — by you, by regulators, by anyone who wants to verify that what we say is happening is actually happening.

For the first time in the history of healthcare, the patient is the protagonist.

Most healthcare technology platforms force you to choose between two worlds.

You either trust the cryptocurrency-native infrastructure that crypto users prefer — public blockchains, self-custody wallets, decentralized everything — at the cost of regulatory clarity and mass-market accessibility.

Or you trust the traditional financial infrastructure — federally-supervised, bank-grade, professionally regulated — at the cost of the patient ownership and transparency that blockchain makes possible.

MyRxWallet is being built so members never have to choose.

The platform is being designed to operate on two parallel settlement rails, with a seamless migration path between them.

The Legacy Bridge. The first rail is built on the Optimism Stack and anchors to the Ethereum public blockchain through Coinbase's Base network — the same architecture used by leading crypto-native applications that serve hundreds of thousands of existing wallet holders. This rail is being designed to onboard members who already hold cryptocurrency, who already operate self-custody wallets, who want their MyRxWallet activity to integrate with the broader Ethereum ecosystem they're familiar with. Genesis on this rail occurred in May 2026.

The Federal-Grade Sovereign Rail. The second rail is being built on permissioned Hyperledger Hyperscale infrastructure — owned, operated, and governed by MyRxWallet, with no dependency on any external blockchain. Architecturally, this rail is designed to mirror the posture of the Federal Reserve's FedNow Service, the Real-Time Payments Network, and the Fedwire Funds Service: federally-grade, permissioned, sovereign settlement. This is the rail being built for the billions of patients, providers, and merchants who don't have cryptocurrency wallets, who don't want to manage seed phrases, who want healthcare-payment infrastructure that operates with the same trust posture as the banking systems they already use.

Why both? Because the world is in transition. The cryptocurrency-native population represents tens of millions of users who deserve a healthcare platform that respects their existing infrastructure choices. The mainstream population represents billions of users who deserve a healthcare platform that doesn't require them to learn a new financial system. MyRxWallet is being designed to serve both, with NFT identity portable between rails, MRT compensation flowing across both rails, and a planned migration path so that members starting on the Legacy Bridge can move to the Sovereign Rail as their needs evolve.

The architecture is the moat. The mission is patient empowerment. The vision is bigger than healthcare.

We will not promise you what we cannot deliver, and we will not promise the same outcome to every member.

The pharmaceutical research industry pays specific, well-documented rates for licensed patient data. Generic demographic data trades at the low end. Bundled clinical-genomic-longitudinal data on patients with chronic conditions, rare diseases, or complete health histories commands premium pricing.

The 23andMe transaction valued each genomic profile at twenty dollars and thirty-three cents. Bundled clinical data — what MyRxWallet members will contribute — commands materially higher pricing in the research licensing market than genomic-only profiles, reflecting the additional commercial value of longitudinal clinical context.

Realistic earnings vary materially by member profile. Here is what designed earnings can look like:

These are designed earnings ranges based on documented industry licensing rates and the eighty-five percent royalty structure. Actual earnings will depend on platform maturity, sustained pharmaceutical demand, the specific data a member chooses to share, the depth and longitudinal completeness of their health record, and the network effects that compound as the platform grows.

Beyond data licensing — the Member Benefits Stack. Members who actively engage with the broader platform — wellness programs, fitness tracking, preventive care milestones, the platform's pharmacy and insurance products (subject to applicable state licensure), clinical trial matching, and the affiliate marketplace — can earn additional MRT through structured reward channels. Engaged members in chronic disease tiers (Tier 2 and above) who participate across multiple value streams are designed to be able to accrue meaningful annual benefits, including travel and lifestyle redemptions, within approximately two years of consistent engagement. Tier 4 and Tier 5 members are designed to reach equivalent benefit thresholds significantly faster.

For network builders. Members who refer other patients, providers, or employer groups to the platform are designed to earn network-effect compensation that materially exceeds individual data licensing alone. Detailed referral economics will be published with the platform's launch documentation.

What we will not do. We will not guarantee that every member, regardless of profile or engagement, will earn the same outcome. The Federal Trade Commission's earnings claim guidelines do not allow that, and we wouldn't try. Different members generate different data with different commercial value, and different members engage with the platform at different intensities. What we will guarantee is the structural opportunity: ownership of your data, eighty-five percent of every royalty paid for that data, full transparency on every transaction, and a redemption network designed to translate earned MRT into real value in your life.

The musicians who write your favorite songs cannot see who streamed them, how much advertising revenue was generated, or how Spotify's algorithm allocated their royalties. They get a check and have to trust the math.

Authors, actors, athletes — every creator class in every industry has the same complaint about every platform that monetizes their work: the books are closed.

MyRxWallet is being designed differently.

Every data licensing transaction will be recorded immutably on the platform's blockchain settlement rails. Every member will see, in real time, on their personal dashboard:

• Which licensing event triggered a royalty
• How much was paid by the buyer
• What percentage flowed to the patient (eighty-five percent)
• The transaction hash that anyone can independently verify
• Aggregate earnings for the month, the year, the lifetime
• Buyer category and consent context (anonymized but verifiable)
• Real-time platform metrics, including the total treasury reserve, total MRT in circulation, and current per-MRT NAV floor

The patient becomes their own auditor. The platform becomes their own bank. The blockchain becomes the proof.

This is what regulators have been demanding from the healthcare industry for two decades. The 21st Century Cures Act mandated patient access. ONC's HTI rules mandate transparency. CMS-0053-F mandates real-time data delivery starting May 2028.

MyRxWallet is being designed to operationalize what the federal government has been requiring all along.

The platform is in active development. The mechanics described below are the designed member experience for the launch product.

The platform is being designed to serve three communities in parallel.

Patients — The people whose data has been monetized for decades without compensation. Every demographic. Every health condition. Every income level. Every age. The platform's economic engine works for the healthy adult who shares modest data and earns a meaningful annual royalty. It works at vastly larger scale for chronic disease patients, rare disease patients, and pediatric oncology families whose data carries premium research value.

Providers — Doctors, nurse practitioners, physician assistants, and clinical staff. The platform is being designed to compensate providers across multiple channels: licensing of de-identified prescribing patterns and clinical outcomes data; clinical trial site participation; quality metric bonuses; practice efficiency tools; and patient acquisition flow through the MyRxWallet network.

Healthcare institutions and government partners — Federally-supervised entities including state Medicaid agencies, the Department of Veterans Affairs, the Centers for Medicare and Medicaid Services, the National Institutes of Health, and academic medical centers are designed to participate as data licensors and as data customers. The transparency framework is designed to give regulators the audit trail they have spent two decades requesting.

This is not a healthcare app. This is being designed as the ownership and economic layer for healthcare itself.

The technology that makes MyRxWallet possible did not exist a decade ago.

Fast Healthcare Interoperability Resources became a federal mandate. Permissioned blockchain infrastructure matured to enterprise grade. Federal payment rails like FedNow demonstrated that sovereign settlement systems can operate at national scale. The Securities and Exchange Commission's guidance on compensation tokens established the regulatory framework. The Genetic Information Privacy Act, state consumer health data statutes, and the Federal Trade Commission's enforcement posture created the compliance environment.

Most importantly, the 23andMe bankruptcy proved beyond dispute what happens when patients do not own the economic rights to their own data.

The window for building the alternative is now.

The platform is in active development. Patient enrollment opens in waves, beginning with founding members who join the early access list now.

Founding members are designed to receive priority enrollment, founding-member NFT designations, and lifetime preferred status on platform benefits.

There is no cost to join the early access list. There is no commitment beyond the act of telling us you want in.

When the platform launches, you will be first.